Skip to content
Review Open access

Cognition endpoints for Parkinson's disease: A roadmap for developing patient-focused assessment tools to accelerate drug development

Sep 2026 · Journal of Parkinson's Disease · 0 citations · 35 references
Medicine

TL;DR

Recommendations are made regarding necessary literature reviews, including qualitative data and related conceptual models, disease models including pathophysiology and neuropsychological profile, and clinical outcome assessment (COA) reviews, including content validity, psychometrics, and fitness-for-purpose.

Abstract

Cognitive dysfunction is a prevalent and impactful feature of Parkinson's disease (PD), with substantial heterogeneity in onset, severity, and progression, and a high lifetime risk of dementia. Despite its clinical importance, effective treatments and fit-for-purpose outcome measures remain limited. This article reports outcomes from a multi-stakeholder roundtable convened by The Michael J. Fox Foundation for Parkinson's Research, outlining priorities to advance patient-focused endpoints and improve clinical trial design to accelerate therapeutic development for cognitive dysfunction. In the context of the current understanding of cognitive impairment across the PD/dementia with Lewy bodies (DLB) spectrum and existing neuropsychological assessment approaches, recommendations are made regarding necessary literature reviews, including qualitative data and related conceptual models, disease models including pathophysiology and neuropsychological profile, and clinical outcome assessment (COA) reviews, including content validity, psychometrics, and fitness-for-purpose. Additionally, novel conceptual models of cognitive impairment across the normal, mild cognitive impairment (MCI) and dementia spectrum are needed and may require further qualitative evidence.

Read PDF

Similar papers

Review Open access Sep 2026

Treatment of Parkinson’s Disease-Related Psychosis

Purpose To provide an updated, clinically oriented overview of therapeutic strategies for Parkinson’s disease-related psychosis (PDP), integrating current evidence on risk factors and available pharmacological and non-pharmacological treatments. Patients and Methods This is a narrative, non-systematic review summarizin...

N. Rocha, Karina Lucia Moreira Sassi, Erin Furr Stimming et al. · 0 citations
Review Open access Sep 2026

Understanding Alzheimer's disease through biomarkers: pathology, progression, and clinical application.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...

Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al. · 0 citations
Review Open access Aug 2026

Prevalence, predictors, and emerging biomarkers for cognitive impairment and neuropsychiatric manifestations in Parkinson's disease in Africa: A systematic review

Background Cognitive impairment and neuropsychiatric manifestations are common disabling non-motor symptoms that can negatively impact quality of life in Parkinson's disease. This review aimed to critically appraise and synthesize evidence on the prevalence, predictors, and emerging biomarkers of cognitive impairment a...

M. Njohjam, F. Niakam, M. Ngoule · 0 citations
Review Open access Sep 2026

Understanding Neuropsychiatric Fluctuations in Parkinson's Disease: From Mechanisms to Management.

BACKGROUND In patients with fluctuating Parkinson's disease (PD), treatment decisions predominantly focus on motor complications, whereas neuropsychiatric symptoms are often regarded as static. Neuropsychiatric fluctuations (NPF), however, are frequent, can rival or exceed motor symptoms in their impact on quality of l...

M. Sousa, D. Amstutz, E. Natera-Villalba et al. · 0 citations
Review Open access Sep 2026

Cognitive Well-Being: A Clinical Review of Brain Health, Dementia Risk Reduction, and Emerging Biomarkers for the Osteopathic Family Physician

Background: As people age, they grow more aware of brain health, and interest in keeping the mind sharp has grown alongside anti-aging culture. Neurologic disease is a leading global burden: stroke is the fifth leading cause of death, migraine is the second most burdensome neurological disorder, and more than 57 millio...

Joey R. Gee · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.